Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Leukemia

  Free Subscription


23.12.2024

6 Am J Hematol
5 Ann Hematol
1 Biochem Biophys Res Commun
2 Blood
2 BMC Cancer
3 Bone Marrow Transplant
12 Br J Haematol
1 Cancer Chemother Pharmacol
1 Cancer Lett
2 Cancer Res
2 Int J Hematol
4 J Clin Oncol
1 J Natl Cancer Inst
1 J Pediatr Hematol Oncol
6 Leuk Lymphoma
2 Leuk Res
9 Leukemia
8 N Engl J Med
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Hematol

  1. GHOSH N, Eyre TA, Brown JR, Lamanna N, et al
    Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.
    Am J Hematol. 2024 Dec 19. doi: 10.1002/ajh.27563.
    PubMed        

  2. GANGAT N, Elbeih A, Ghosoun N, McCullough K, et al
    Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.
    Am J Hematol. 2024 Dec 13. doi: 10.1002/ajh.27564.
    PubMed         Abstract available

  3. CAIROLI R, Gatti A, Grillo G, Stefanucci MR, et al
    Efficacy of Midostaurin Combined With Intensive Chemotherapy in Core Binding Factor Leukemia: A Phase II Clinical Trial.
    Am J Hematol. 2024 Dec 10. doi: 10.1002/ajh.27547.
    PubMed         Abstract available

  4. GUERINEAU H, Cayuela JM, Dulucq S, Tran Quang V, et al
    Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia: A Report From the RESIDIAG Study.
    Am J Hematol. 2024 Dec 10. doi: 10.1002/ajh.27553.
    PubMed        

  5. LUFT T, Gras L, Koster L, Kroger N, et al
    Methotrexate Versus Mycophenolate Mofetil Prophylaxis in Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Malignancies: A Retrospective Analysis on Behalf of the Chronic Malignancies Working Party of the EBMT.
    Am J Hematol. 2025;100:38-51.
    PubMed         Abstract available

  6. RECHER C, Dumas PY, Berard E, Tavitian S, et al
    Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.
    Am J Hematol. 2025;100:23-32.
    PubMed         Abstract available


    Ann Hematol

  7. SUGIHARA A, Kubota Y, Nagaie T, Fujita M, et al
    Epstein-Barr virus-associated lymphoproliferative disease during remission after induction therapy with dasatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a case report.
    Ann Hematol. 2024 Dec 21. doi: 10.1007/s00277-024-06153.
    PubMed         Abstract available

  8. MA JF, Yan CL, Jia X, Zhu HJ, et al
    Clinical outcomes and safety of CAR-T cells in treatment of T-Cell acute lymphoblastic leukemia/lymphoma.
    Ann Hematol. 2024 Dec 18. doi: 10.1007/s00277-024-06132.
    PubMed         Abstract available

  9. TANG X, Liu S, Hu Y, Chen F, et al
    Clearing MRD positivity with blinatumomab in pediatric B-cell acute lymphoblastic leukemia: insights from droplet digital PCR and flow cytometry.
    Ann Hematol. 2024 Dec 13. doi: 10.1007/s00277-024-06126.
    PubMed         Abstract available

  10. LI W, Ma R, Fan X, Xiao Z, et al
    M1 macrophage-derived exosomes alleviate leukemia by causing mitochondrial dysfunction.
    Ann Hematol. 2024 Dec 12. doi: 10.1007/s00277-024-06138.
    PubMed         Abstract available

  11. SANCHEZ-MENDOZA SE, de Deus-Wagatsuma VM, do Nascimento MC, Lima K, et al
    All-trans retinoic acid potentiates cell death induced by quizartinib in acute myeloid leukemia with FLT3-ITD mutations.
    Ann Hematol. 2024 Dec 11. doi: 10.1007/s00277-024-06089.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  12. SAWAI S, Oda Y, Saito Y, Kuwabara T, et al
    Analysis of synthetic polymer hydrogel-based generation of leukemia stem cells.
    Biochem Biophys Res Commun. 2024;744:151149.
    PubMed         Abstract available


    Blood

  13. CUI B, Ai L, Lei M, Duan Y, et al
    Single-cell epigenetic and clonal analysis decodes disease progression in pediatric acute myeloid leukemia.
    Blood. 2024 Dec 11:blood.2024025618. doi: 10.1182/blood.2024025618.
    PubMed         Abstract available

  14. BOUDIA F, Baille M, Babin L, Aid Z, et al
    Progressive chromatin rewiring by ETO2::GLIS2 revealed in a human iPSC model of pediatric leukemia initiation.
    Blood. 2024 Dec 10:blood.2024024505. doi: 10.1182/blood.2024024505.
    PubMed         Abstract available


    BMC Cancer

  15. RADWAN RE, El-Kholy WM, Elsaed A, Darwish A, et al
    Genetic predisposition meets cytokine imbalance: the influence of TNF-alpha (-308) polymorphism and TGF-beta levels in pediatric acute lymphoblastic leukemia in Egypt.
    BMC Cancer. 2024;24:1509.
    PubMed         Abstract available

  16. JI X, Yang C, Niu C
    Proteomic and metabolomic exploration in relapse acute myeloid leukemia bone marrow supernatant combined with genetic characteristics.
    BMC Cancer. 2024;24:1545.
    PubMed         Abstract available


    Bone Marrow Transplant

  17. WANG MM, Huang SM, Huang YH, Zhang J, et al
    Quantification of the FLT3 internal tandem duplication is a reliable marker for monitoring measurable residual disease in acute myeloid leukemia with FLT3-ITD mutations.
    Bone Marrow Transplant. 2024 Dec 10. doi: 10.1038/s41409-024-02495.
    PubMed        

  18. BLACKMON A, Afkhami M, Yang D, Mokhtari S, et al
    Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual disease.
    Bone Marrow Transplant. 2024 Dec 18. doi: 10.1038/s41409-024-02491.
    PubMed         Abstract available

  19. DUQUE-AFONSO J, Finke J, Ngoya M, Galimard JE, et al
    Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Part
    Bone Marrow Transplant. 2024 Dec 19. doi: 10.1038/s41409-024-02499.
    PubMed         Abstract available


    Br J Haematol

  20. NARESH KN
    Understanding splenic B-cell lymphoma/leukaemia with prominent nucleoli: Diagnosis, underpinnings for disease classification and future directions.
    Br J Haematol. 2024 Sep 10. doi: 10.1111/bjh.19754.
    PubMed         Abstract available

  21. ASHOURI K, Hom B, Ginosyan AA, Rahimi Y, et al
    Philadelphia-like B-cell acute lymphoblastic leukaemia: Disease features and outcomes in the era of immunotherapy.
    Br J Haematol. 2024;205:2234-2247.
    PubMed         Abstract available

  22. LIU W, Wang C, Ouyang W, Hao J, et al
    Efficacy and safety of olverembatinib in adult BCR::ABL1-positive ALL with T315I mutation or relapsed/refractory disease.
    Br J Haematol. 2024;205:2228-2233.
    PubMed         Abstract available

  23. KAMIYA LJ, Barozzi S, Isidori F, Ganiewich D, et al
    Two novel families with RUNX1 variants indicate glycine 168 as a new mutational hotspot: Implications for FPD/AML diagnosis.
    Br J Haematol. 2024;205:2315-2320.
    PubMed         Abstract available

  24. TERUEL-MONTOYA R, Rivera J, Lozano ML
    The importance of genetic variant cleaners: From patient to wet lab and back to clinical practice.
    Br J Haematol. 2024;205:2122-2124.
    PubMed         Abstract available

  25. JAYNE S, Lopez C, Put N, Nagel I, et al
    The chromosomal translocation t(1;6)(p35.3;p25.2), recurrent in chronic lymphocytic leukaemia, leads to RCC1::IRF4 fusion.
    Br J Haematol. 2024;205:2321-2326.
    PubMed         Abstract available

  26. BOUSSI L, Biswas J, Abdel-Wahab O, Stein E, et al
    Therapeutic strategies targeting aberrant RNA splicing in myeloid malignancies.
    Br J Haematol. 2024;205:2153-2162.
    PubMed         Abstract available

  27. PULA AE, Robak T
    The discovery of the RCC1::IRF4 Fusion in CLL patients with t(1;6)(p35.3;p25.2) chromosomal translocation.
    Br J Haematol. 2024;205:2125-2127.
    PubMed         Abstract available

  28. KONDO T
    A new face in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:2131-2133.
    PubMed         Abstract available

  29. MORIGUCHI M, Nakamae H, Nishimoto M, Sugita J, et al
    Comparison of HLA-haploidentical donors with post-transplant cyclophosphamide versus HLA-matched unrelated donors in peripheral blood stem cell transplantation for acute myeloid leukaemia.
    Br J Haematol. 2024;205:2376-2386.
    PubMed         Abstract available

  30. HUGUET F, Guerci-Bresler A, Roth-Guepin G, Cayssials E, et al
    Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study.
    Br J Haematol. 2024;205:2295-2304.
    PubMed         Abstract available

  31. FROST EL, Chonat S, Williams KM, Aumann W, et al
    Fatal thrombotic microangiopathy during induction for acute myeloid leukemia: A case report and review of vascular complications in germline GATA2 haploinsufficiency.
    Br J Haematol. 2024 Dec 8. doi: 10.1111/bjh.19935.
    PubMed        


    Cancer Chemother Pharmacol

  32. MATSUI M, Yasu T, Makimoto A, Yuza Y, et al
    Pharmacokinetic analysis of crushed venetoclax tablets combined with azacitizine for recurrent pediatric acute myeloid leukemia (AML).
    Cancer Chemother Pharmacol. 2024;95:1.
    PubMed         Abstract available


    Cancer Lett

  33. VAN TRIMPONT M, Schalk AM, Hofkens K, Peeters E, et al
    A human-like glutaminase-free asparaginase is highly efficacious in ASNS(low) leukemia and solid cancer mouse xenograft models.
    Cancer Lett. 2024 Dec 19:217404. doi: 10.1016/j.canlet.2024.217404.
    PubMed         Abstract available


    Cancer Res

  34. LIU X, Liu Y, Rao Q, Mei Y, et al
    Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells.
    Cancer Res. 2024;84:4233-4245.
    PubMed         Abstract available

  35. CERMAKOVA K, Hodges HC
    Pharmacologic Blockade of a Pioneer Transcription Factor.
    Cancer Res. 2024;84:4124-4125.
    PubMed         Abstract available


    Int J Hematol

  36. ARAI H, Hosono N, Chi S, Fukushima K, et al
    A practice-oriented genome-profiling study for acute myeloid leukemia using the novel HANDLE system: HM-screen-JAPAN02.
    Int J Hematol. 2024 Dec 16. doi: 10.1007/s12185-024-03895.
    PubMed         Abstract available

  37. KOHSO A, Toyoda H, Hanaki R, Niwa K, et al
    Inotuzumab ozogamicin for relapse prevention in a boy with Down syndrome and relapsed acute lymphoblastic leukemia.
    Int J Hematol. 2024 Dec 9. doi: 10.1007/s12185-024-03890.
    PubMed         Abstract available


    J Clin Oncol

  38. ROY A, Brander DM, Hill EG, Halabi S, et al
    Statistical Perspectives and Meta-Analytic Approaches in Surrogate End Point Evaluation for Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2024 Dec 12:JCO2401881. doi: 10.1200/JCO-24-01881.
    PubMed        

  39. SHADMAN M, Munir T, Robak T, Brown JR, et al
    Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.
    J Clin Oncol. 2024 Dec 8:JCO2402265. doi: 10.1200/JCO-24-02265.
    PubMed         Abstract available

  40. DAVIDS MS, Ryan CE, Lampson BL, Ren Y, et al
    Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naive Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
    J Clin Oncol. 2024 Dec 7:JCO2402503. doi: 10.1200/JCO-24-02503.
    PubMed         Abstract available

  41. KANTARJIAN H, Short NJ, Haddad FG, Jain N, et al
    Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL.
    J Clin Oncol. 2024;42:4246-4251.
    PubMed         Abstract available


    J Natl Cancer Inst

  42. BROWN JC, Ma C, Shi Q, Couture F, et al
    Inflammation, Physical Activity, and Disease-Free Survival in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance).
    J Natl Cancer Inst. 2024 Aug 24:djae203. doi: 10.1093.
    PubMed         Abstract available


    J Pediatr Hematol Oncol

  43. MILLER DR
    Contributions of Pediatric Hematology/Oncology to the Diagnosis, Treatment, and Cure of Acute Lymphoblastic Leukemia-Part 2b (Numbers 16 to 20).
    J Pediatr Hematol Oncol. 2024 Dec 9. doi: 10.1097/MPH.0000000000002981.
    PubMed         Abstract available


    Leuk Lymphoma

  44. BOHN JP, Stolzlechner V, Gobel G, Pirklbauer M, et al
    Reduced prognostic value of beta-2-microglobulin for time to first treatment in CLL patients with compromised kidney function.
    Leuk Lymphoma. 2024;65:2108-2115.
    PubMed         Abstract available

  45. TASHAKORI M, Yohe S, Linden MA, McKenna RW, et al
    The prognostic effect of blast count in TP53 mutant myeloid neoplasms -the Minnesota experience.
    Leuk Lymphoma. 2024;65:2151-2162.
    PubMed         Abstract available

  46. ISHIKAWA C, Mori N
    ML385, a selective inhibitor of Nrf2, demonstrates efficacy in the treatment of adult T-cell leukemia.
    Leuk Lymphoma. 2024 Dec 17:1-12. doi: 10.1080/10428194.2024.2441875.
    PubMed         Abstract available

  47. SHELLEY CS, Galiegue-Zouitina S, Andritsos LA, Epperla N, et al
    The role of the JunD-RhoH axis in the pathogenesis of hairy cell leukemia and its ability to identify existing therapeutics that could be repurposed to treat relapsed or refractory disease.
    Leuk Lymphoma. 2024 Dec 17:1-19. doi: 10.1080/10428194.2024.2438800.
    PubMed         Abstract available

  48. OLIAI C, Park S, Damon LE, Jonas BA, et al
    CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial.
    Leuk Lymphoma. 2024 Dec 17:1-7. doi: 10.1080/10428194.2024.2438809.
    PubMed         Abstract available

  49. DAMPMANN M, Kibler A, von Tresckow J, Reinhardt HC, et al
    Single-cell analysis of a bi-clonal chronic lymphocytic leukemia reveals two clones with distinct gene expression pattern.
    Leuk Lymphoma. 2024 Dec 17:1-9. doi: 10.1080/10428194.2024.2438804.
    PubMed         Abstract available


    Leuk Res

  50. KARUBE K, Sakihama S, Takatori M, Morichika K, et al
    Recent progress in pathological understanding of adult T-cell leukemia/lymphoma in the new classification era.
    Leuk Res. 2024;148:107634.
    PubMed         Abstract available

  51. LI M, Zhang S, Wei J, Liu M, et al
    The increase in the expression of circRNAs may contributes to a poor prognosis in acute myeloid leukemia: A systematic review and meta-analysis.
    Leuk Res. 2024;148:107639.
    PubMed         Abstract available


    Leukemia

  52. HAMPEL PJ, Rabe KG, Wang Y, Hwang SR, et al
    Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy era.
    Leukemia. 2024 Dec 10. doi: 10.1038/s41375-024-02492.
    PubMed        

  53. MITSUYUKI S, Shimomura Y, Mizumaki H, Yanada M, et al
    Allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with t(16;21)(p11;q22)/FUS::ERG.
    Leukemia. 2024 Dec 10. doi: 10.1038/s41375-024-02495.
    PubMed        

  54. SHIMA H, Tono C, Tanizawa A, Ito M, et al
    Growth retardation and adult height in pediatric patients with chronic-phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Leukemia. 2024 Dec 12. doi: 10.1038/s41375-024-02488.
    PubMed        

  55. ARGYRIADI EA, Steffen IG, Chen-Santel C, Lissat A, et al
    Prognostic relevance of treatment deviations in children with relapsed acute lymphoblastic leukemia who were treated in the ALL-REZ BFM 2002 study.
    Leukemia. 2024 Dec 11. doi: 10.1038/s41375-024-02474.
    PubMed         Abstract available

  56. GERRITSEN M, In 't Hout FEM, Knops R, Mandos BLR, et al
    Acute myeloid leukemia associated RUNX1 variants induce aberrant expression of transcription factor TCF4.
    Leukemia. 2024 Dec 12. doi: 10.1038/s41375-024-02470.
    PubMed        

  57. ORVAIN C, Milano F, Rodriguez-Arboli E, Othus M, et al
    Relationship between donor source, pre-transplant measurable residual disease, and outcome after allografting for adults with acute myeloid leukemia.
    Leukemia. 2024 Dec 12. doi: 10.1038/s41375-024-02497.
    PubMed         Abstract available

  58. BALESTRA T, Niswander LM, Bagashev A, Loftus JP, et al
    Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia.
    Leukemia. 2024 Dec 16. doi: 10.1038/s41375-024-02493.
    PubMed         Abstract available

  59. NABKI J, Al Deeban B, Sium AM, Cosentino C, et al
    Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement.
    Leukemia. 2024 Dec 17. doi: 10.1038/s41375-024-02499.
    PubMed         Abstract available

  60. SHI Z, Li J, Ding J, Zhang Y, et al
    ADAR1 is required for acute myeloid leukemia cell survival by modulating post-transcriptional Wnt signaling through impairing miRNA biogenesis.
    Leukemia. 2024 Dec 19. doi: 10.1038/s41375-024-02500.
    PubMed         Abstract available


    N Engl J Med

  61. FALINI B, Tiacci E
    Hairy-Cell Leukemia. Reply.
    N Engl J Med. 2024;391:2388.
    PubMed        

  62. HERMEL DJ, Saven A
    Hairy-Cell Leukemia.
    N Engl J Med. 2024;391:2387-2388.
    PubMed        

  63. REINHOLD I, Cornely OA, Stemler J
    Hairy-Cell Leukemia.
    N Engl J Med. 2024;391:2386-2387.
    PubMed        

  64. ABRUZZESE E
    Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. Reply.
    N Engl J Med. 2024;391:2276.
    PubMed        

  65. HOCHHAUS A, Cortes JE, Hughes TP
    Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. Reply.
    N Engl J Med. 2024;391:2275-2276.
    PubMed        

  66. PUNWANI N
    Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
    N Engl J Med. 2024;391:2275.
    PubMed        

  67. GAMBACORTI-PASSERINI C, Piazza R
    Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
    N Engl J Med. 2024;391:2274-2275.
    PubMed        

  68. GUPTA S, Rau RE, Kairalla JA, Rabin KR, et al
    Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.
    N Engl J Med. 2024 Dec 7. doi: 10.1056/NEJMoa2411680.
    PubMed         Abstract available


    PLoS One

  69. NAGEL S, Meyer C, Pommerenke C
    IRX-related homeobox gene MKX is a novel oncogene in acute myeloid leukemia.
    PLoS One. 2024;19:e0315196.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.